Wells Fargo & Company Praxis Precision Medicines, Inc. Transaction History

Wells Fargo & Company

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$0.87 - $1.71 $501 - $984	576 Added 159.12%	938 $1,000
Q2 2023 Aug 15, 2023	SELL	$0.83 - $1.18 $6,761 - $9,612	-8,146 Reduced 95.75%	362 $0
Q1 2023 May 12, 2023	BUY	$0.8 - $4.98 $6,806 - $42,369	8,508 New	8,508 $6,000
Q3 2022 Nov 14, 2022	SELL	$2.5 - $37.95 $7,032 - $106,753	-2,813 Reduced 95.1%	145 $0
Q2 2022 Aug 12, 2022	SELL	$1.75 - $11.34 $19 - $124	-11 Reduced 0.37%	2,958 $7,000
Q1 2022 May 16, 2022	SELL	$10.21 - $20.29 $134,047 - $266,387	-13,129 Reduced 81.56%	2,969 $31,000
Q4 2021 Feb 14, 2022	BUY	$16.76 - $22.99 $244,193 - $334,964	14,570 Added 953.53%	16,098 $318,000
Q3 2021 Nov 15, 2021	BUY	$13.15 - $22.56 $17,660 - $30,298	1,343 Added 725.95%	1,528 $28,000
Q2 2021 Aug 16, 2021	SELL	$18.28 - $33.05 $29,851 - $53,970	-1,633 Reduced 89.82%	185 $3,000
Q1 2021 May 13, 2021	SELL	$29.34 - $60.2 $114,572 - $235,081	-3,905 Reduced 68.23%	1,818 $59,000
Q4 2020 Feb 09, 2021	BUY	$27.25 - $55.82 $155,951 - $319,457	5,723 New	5,723 $315,000

75K

Ticker PRAX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,576,100
Market Cap $3.54B
Description
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of ...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.